Fast-food chain McDonald’s, an economic indicator because of its mammoth global presence, posted its worst earnings report since 2020.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
By licensing a drug from Hansoh, Merck signaled that it isn’t prepared to fully challenge its rivals’ dominance in the GLP-1 space.
With Trump expected to chase increased oil exports and more drilling in the US, OPEC+’s fear of losing market share looms larger than ever.
Don’t get too excited for cheaper Taylor Swift tickets: The rules just force sellers to present all the extra fees upfront.
Novo Nordisk, maker of weight-loss drug Wegovy, struck a deal with online telehealth storefronts that sold cheap knockoffs during shortages.
It’s part of the EU’s goal to build its own spacefaring infrastructure, reducing its dependence on US private companies.
Besides being your one-stop-retail-shop for everything, Walmart would like to be your virtual banker, too.
The Fed may have cracked inflation, but eggflation is proving harder to beat. Unsurprisingly, egg producer stocks are soaring.
Reducing beverage-wait times is part of Starbucks CEO Brian Niccol’s turnaround plan, which includes tech updates focused on efficiency.
A day after antitrust enforcers successfully blocked Albertsons’ planned sale to Kroger, the former filed a lawsuit against the latter.
Amazon touts itself as the everything store, and now there’s one more market it’s absorbing into its everythingness.
The transaction would create the world’s largest advertising agency — that is, if you don’t count Big Tech players like Google and Amazon.
To prepare for a slowdown of global trade, US retailers spent months building a massive inventory to prevent empty shelves.
Hertz’s recent track record leaves much to be desired: the rental-car company lost nearly $2.9 billion last year.
Investor worries about a fresh batch of US tariffs have dragged LVMH shares in Paris down 23.6% so far this year.
The company plans to seek regulatory approval for the revolutionary weight loss treatment by the end of the year.